dpp-4 inhibitor and glp-1 receptor agonist combination not recommended ada Frontiers | inhibitors for treating T2DM Can dipeptidyl peptidase‑4 (DPP‑4) inhibitors
Description
Patient and insurer spending on GLP-1s jumped from $13.7 billion in 2018 to $71.7 billion in 2023, a financial surge that generated headlines implying innovation rather than the scaling of proven science
Batterham, M
The antidiabetic effect and potential mechanisms of natural polysaccharides based on the regulation of gut microbiota
While insurers receive rebates to offset some of their costs, the list prices of GLP-1 drugs are about $1,000 per month, and growing demand for these medications could put upward pressure on premiums
[DOI] [PubMed] [Google Scholar] 65.Trumper A, Trumper K, Horsch D
